Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Letrozole (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Nov 2006 New trial record.